While selective targeting of APC/C or CDK1/2 have yielded limited clinical benefits (due to toxicity)13–15, CDK4/6 inhibitors such as palbociclib have demonstrated remarkable efficacy against several breast cancer subtypes16. Here, CDK4 is linked to breast carcinoma.